ASCO® 2026: 3 immediate observations from the congress floor

Written by Dan Parker, EVP at Inizio 

The 2026 ASCO® Annual Meeting did not disappoint and was arguably one of the most consequential meetings in recent years. From the congress floor, three structural shifts stood out. 

Oncology approvals are accelerating, and so is complexity 

The pace of oncology approvals has fundamentally changed, with FDA oncology approval activity expanding significantly over the past four years compared to the previous two decades. However, the composition matters. The surge is driven overwhelmingly by indication expansions rather than truly novel mechanisms. More options do not automatically mean more clarity; for HCPs, payers, and patients, the decision landscape is becoming genuinely complex. 

China has arrived as a first-tier oncology innovator 

In the first instance of a Chinese-originated study reaching ASCO®’s Plenary Session, ivonescimab, a bispecific antibody developed by Akeso, presented overall survival data from the HARMONi-6 trial. A growing share of the global oncology pipeline now originates in China, representing roughly 28% of large pharma’s in-licensed asset deal value over the last five years. Oncology represents over 60% of that output, with ADCs and bispecific antibodies the dominant modalities. 

Diagnostics move to the centre of cancer care 

Molecular diagnostics are becoming the scaffolding of cancer care. Multi-cancer early detection tests, ctDNA-based minimal residual disease monitoring, and companion diagnostics are moving from exploratory tools to foundational stages in each patient’s journey: from screening through treatment selection to post-treatment surveillance. The FDA’s 2024 guidance standardizing the use of ctDNA for solid tumor drug development signals that diagnostics will increasingly shape the approval pathway itself, not just follow it. 

What does this mean for pharma? 

The traditional model of pharma engaging HCPs primarily through data disclosure at congress is no longer sufficient. As indication expansions multiply, Chinese-partnered assets enter Western pipelines, and biomarker stratification fragments patient populations, the HCP faces a navigation challenge that pure data presentation doesn’t resolve. 

The pharma companies leading this shift are those who can intelligently integrate their clinical data, congress presence, and HCP engagement into a coherent decision-support architecture – connecting the evidence to the pathway, and the pathway to the patient. 

That’s not a communications challenge. It’s a commercialization one. Getting it right requires connecting strategy, medical, and engagement capabilities around a single coherent view of what the HCP really needs to navigate, before, during, and long after the congress floor empties. 

Navigating the future of oncology 

As oncology grows more complex, the need for connected commercialization strategies has never been greater. If you’d like to discuss how these trends could impact your organization, start the conversation today.